Parecoxib Sodium, an Injectable COX-2-Specific Inhibitor, Does Not Affect Unfractionated Heparin-Regulated Blood Coagulation Parameters

Journal of Clinical Pharmacology

Volumn 44, Issue 5, 2004, Pages 474-480

  Noveck, Robert J ^a   Hubbard, Richard C ^b  

^a General Clinical Research Center New Orleans   (United States)

^b PFIZER INC   (United States)

Author keywords

COX 2 specific inhibitor; Drug interaction; Heparin; LMWH; Parecoxib sodium; UFH

Indexed keywords

HEPARIN; PARECOXIB;

ADULT; ANALGESIA; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; HEADACHE; HEMOSTASIS; HUMAN; INFECTION; INFLAMMATION; INJECTION SITE; MALE; NAUSEA; PAIN; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PAIN; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTE COUNT; THROMBOSIS; URINARY TRACT INFECTION;

ADULT; BLOOD COAGULATION FACTORS; CYCLOOXYGENASE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; ISOENZYMES; ISOXAZOLES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTHROMBIN TIME;

EID: 1942443926     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004264166     Document Type: Article

References (41)

1. Po AL, Zhang WY: Analgesic efficacy of ibuprofen alone and in combination with codeine or caffeine in post-surgical pain: a metaanalysis. Eur J Clin Pharmacol 1998;53:303-311.
2. Baumgartner H, Kuttelwascher M, McCaskey D, Winters L: The comparative efficacy of naproxen sodium and pirprofen in the treatment of post-operative pain. J Int Med Res 1987;15:179-187.
3. Mansfield M, Firth F, Glynn C, Kinsella J: A comparison of ibuprofen arginine with morphine sulphate for pain relief after orthopaedic surgery. Eur J Anaesthesiol 1996;13:492-497.
4. Kiersch TA, Halladay SC, Koschik M: A double-blind, randomized study of naproxen sodium, ibuprofen, and placebo in postoperative dental pain. Clin Ther 1993;15:845-854.
5. Gillis JC, Brogden RN: Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997;53:139-188.
6. O'Hara DA, Fragen RJ, Kinzer M, Pemberton D: Ketorolac tromethamine as compared with morphine sulfate for treatment of postoperative pain. Clin Pharmacol Ther 1987;41:556-561.
7. Lewis S: Ketorolac in Europe. Lancet 1994;343:784.
8. Singh G, Rosen Ramey D: NSAID induced gastrointestinal complications: the ARAMIS perspective 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 1998;51(Suppl.):8-16.
9. Strom BL, Berlin JA, Kinman JL, Spitz PW, Hennessy S, Feldman H, et al: Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study. JAMA 1996;275:376-382.
10. Spowart K, Greer LA, McLaren M, Lloyd J, Bullingham RE, Forbes CD: Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. Thromb Haemost 1988;60:382-386.
11. Choo V, Lewis S: Ketorolac doses reduced. Lancet 1993;342:109.
12. Greer IA, Gibson JL, Young A, Johnstone J, Walker ID: Effect of ketorolac and low-molecular-weight heparin individually and in combination on haemostasis. Blood Coagul Fibrinolysis 1999;10:367-373.
13. Verhaeghe R: The use of low-molecular-weight heparins in cardiovascular disease. Acta Cardiol 1998;53:15-21.
14. Heaton D, Pearce M: Low molecular weight versus unfractionated heparin: a clinical and economic appraisal. Pharmacoeconomics 1995;8:91-99.
15. Weitz IC, Israel VK, Waisman JR, Presant CA, Rochanda L, Liebman HA: Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost 2002;88:213-220.
16. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-277.
17. Dunn CJ, Goa KL: Enoxaparin: a pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty. Pharmacoeconomics 1996;10:179-190.
18. Breddin HK: Reviparin sodium - a new low molecular weight heparin. Expert Opin Pharmacother 2002;3:173-182.
19. Samama CM, Vray M, Barre J, Fiessinger JN, Rosencher N, Lecompte T, et al: Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002;162:2191-2196.
20. Dunn CJ, Sorkin EM: Dalteparin sodium: a review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs 1996;52:276-305.
21. Bannwarth B: Gastrointestinal tolerance of nonsteroidal antiinflammatory agents. Drugs 2000;59(1):17-23.
22. Everts B, Wahrborg P, Hedner T: COX-2-specific inhibitors: the emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol 2000;19:331-343.
23. Connelly CS, Panush RS: Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch Intern Med 1991;151:1963-1966.
24. Niemi TT, Taxell C, Rosenberg PH: Comparison of the effect of intravenous ketoprofen, ketorolac and diclofenac on platelet function in volunteers. Acta Anaesthesiol Scand 1997;41:1353-1358.
25. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al: Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-1602.
26. Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, et al: Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000;27:1876-1883.
27. Karim A, Laurent A, Kuss M, Hubbard RC, Quian J: Single dose tolerability and pharmacokinetics of parecoxib sodium, a COX-2 specific inhibitor following intramuscular administration [abstract]. Anesthesiology 2000;94:A944.
28. Karim A, Laurent A, Kuss ME, Qian J, Hubbard RC: Single dose tolerability and pharmacokinetics of parecoxib sodium, a COX-2 specific inhibitor following intravenous administration [abstract]. Anesthesiology 2000;94:A945.
29. Karim A, Laurent A, Slater ME, Kuss ME, Qian J, Crosby-Sessoms SL, et al: A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol 2001;41:1111-1119.
30. Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, et al: N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 2000;43:1661-1663.
31. Barton SF, Langeland FF, Snabes MC, LeComte D, Kuss ME, Dhadda SS, et al: Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 2002;97:306-314.
32. Rasmussen GL, Steckner K, Hogue C, Torri S, Hubbard RC: Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. Am J Orthop 2002;31:336-343.
33. Daniels SE, Grossman EH, Kuss ME, Talwalker S, Hubbard RC: A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clin Ther 2001;23:1018-1031.
34. Noveck RJ, Laurent A, Kuss M, Talwalker S, Hubbard RC: Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals. Clin DrugInvest 2001;21:465-476.
35. Leese PT, Talwalker S, Kent JD, Recker DP: Valdecoxib does not impair platelet function. Am J Emerg Med 2002;20:275-281.
36. Leese PT, Recker DP, Kent JD: The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol 2003;43:504-513.
37. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM: Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002;14:1101-1111.
38. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP: Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002; 51:530-537.
39. Harris SI, Kuss M, Hubbard RC, Goldstein JL: Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 2001;23:1422-1428.
40. Stoltz RR, Harris SI, Kuss ME, LeComte D, Talwalker S, Dhadda S, et al: Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol 2002;97:65-71.
41. Levine MN, Raskob G, Landefeld S, Kearon C: Hemorrhagic complications of anticoagulant treatment. Chest 2001;119:108S-121S.